58794-09-5

Basic information

• Product Name: 7-Bromoisoquinoline
• Synonyms: 7-BROMOISOQUINOLINE;7-isoquinoline;isoquinolin-7-amine;7-Bromo-2-azanaphthalene
• CAS NO: 58794-09-5
• Molecular Formula: C₉H₆BrN
• Molecular Weight: 208.05
• EINECS: -0
• Product Categories: Isoquinoline Derivertives;Building Blocks;Isoquinoline;Aromatics;Heterocycles
• Mol File: 58794-09-5.mol
• Article Data: 4

Chemical Properties

• Melting Point: 69.0 to 73.0 °C
• Boiling Point: 312.345 °C at 760 mmHg
• Flash Point: 113℃
• Appearance: /
• Density: 1.565 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Acetonitrile (Slightly), Chloroform (Slightly), Methanol (Slightly)
• PKA: 4.62±0.10(Predicted)
• CAS DataBase Reference: 7-Bromoisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromoisoquinoline(58794-09-5)
• EPA Substance Registry System: 7-Bromoisoquinoline(58794-09-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 58794-09-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromoisoquinoline is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its chemical properties make it a valuable building block in the creation of a wide range of medications, contributing to the advancement of healthcare and treatment options.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 7-Bromoisoquinoline serves as a key component in the synthesis of novel drug candidates. Its unique structure allows researchers to explore new avenues in drug design, potentially leading to the discovery of more effective and targeted therapies for various medical conditions.
Used in Drug Development:
7-Bromoisoquinoline is utilized in the drug development process to create new and improved pharmaceuticals. Its role as a synthetic intermediate enables the production of innovative drugs with enhanced efficacy, safety, and selectivity, ultimately benefiting patients and the healthcare industry as a whole.

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 22483-09-6 2,2-dimethoxyethylamine 
• 497863-61-3 m-bromobenzalaminoacetal 
• 7664-93-9 sulfuric acid 
• 63927-20-8 (3-bromo-benzylidenamino)-acetaldehyde diethylacetal 

Downstream Products

• 76518-57-5 isoquinolin-5-ylmethanol 
• 23707-37-1 7-aminoisoquinoline 
• 24464-41-3 7-phenyl-1,2,3,4-tetrahydro-isoquinoline 
• 70125-65-4 7-phenylisoquinoline 
• 2007916-56-3 methyl 4-bromoisoquinoline-7-carboxylate 
• 223671-18-9 7-bromo-isoquinoline N-oxide 
• 1204298-71-4 C₁₀H₇F₂N 
• 1577232-99-5 2,2-difluoro-2-(isoquinolin-7-yl)-1-phenylethanone 

Relevant articles and documents

CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME

The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

ANGIOGENESIS INHIBITORS

Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis:

Discovery of potent and practical antiangiogenic agents inspired by cortistatin A

The discovery that cortistatins A and J show noteworthy antiangiogenic activity prompted an investigation of the possibility that simpler and much more easily made compounds based on a steroid core might have useful bioactivity. These studies have led to

3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors

The structure-based design and synthesis of a novel series of c-Jun N-terminal kinase (JNK) inhibitors with selectivity against p38 is reported. The unique structure of 3,5-disubstituted quinolines (2) was developed from the previously reported 4-(2,7-phenanthrolin-9-yl)phenol (1). The X-ray crystal structure of 16a in JNK3 reveals an unexpected binding mode for this new scaffold with protein.